Reproducibility of serology assays for pandemic influenza H1N1: Collaborative study to evaluate a candidate WHO International Standard

Vaccine

Volumn 30, Issue 2, 2012, Pages 210-217

  Wood, John M ^a   Major, Diane ^a   Heath, Alan ^a   Newman, Robert W ^a   Höschler, Katja ^b   Stephenson, Iain ^c   Clark, Tristan ^c   Katz, Jacqueline M ^d   Zambon, Maria C ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antibody standard; Haemagglutination inhibition; Influenza; Neutralisation; Pandemic; Serology

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; MIFAMURTIDE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; X 179A;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; FREEZE DRYING; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA VIRUS A H1N1; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SERUM; VIRUS CONCENTRATION; VIRUS NEUTRALIZATION;

ANTIBODIES, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERNATIONAL COOPERATION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SEROLOGIC TESTS; WORLD HEALTH ORGANIZATION;

EID: 84355162724     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.019     Document Type: Article

References (22)

1. World Health Organisation. [accessed 22.08.11]. http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/.
2. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(November (20)):1945-1952.
3. Miller E., Höschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375(March (9720)):1100-1108.
4. McVernon J, Laurie K, Nolan T, Owen R, Irving D, Capper H, et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October-December 2009. Euro Surveill 2010;15(October (40)):pii: 19678.
5. Zambon M. Laboratory diagnosis of influenza. Influenza 1997, 123-156. Blackwell. K.G. Nicholson, R.G. Webster, A.J. Hay (Eds.).
6. Potter C.W. Determinants of immunity to influenza infection in man. Br Med Bull 1979, 35:69-75.
7. Wood J.M., Newman R.W., Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol (Basel) 2003, 115:9-16.
8. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines, September 1996; CPMP/BWP/214/96. Circulaire No 96-0661. p. 1-22.
9. US Food and Drug Administration Guidance for Industry. Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. [accessed 22.08.11]. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm.
10. Stephenson I., Das R.G., Wood J.M., Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: international collaborative study. Vaccine 2007, 25:4056-4063.
11. Wood J.M., Gaines-Das R.E., Taylor J., Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994, 12:167-175.
12. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009, 15(August (8)):1252-1259.
13. Ferguson M., Heath A. Report of a collaborative study to calibrate the second international standard for parvovirus B19 antibody. Biologicals 2004, 32:207-212.
14. World Health Organisation. Norms and standards: quality, safety and efficacy of medicines. [accessed 22.08.11]. http://www.who.int/medicines/areas/quality_safety/en.
15. World Health Organisation. Report of a WHO collaborative study to assess the suitability of a candidate International Standard for antibody to influenza H5N1 virus. [accessed 02.08.11]. http://whqlibdoc.who.int/hq/2008/WHO_BS_08.2085_eng.pdf.
16. World Health Organisation. WHO Expert Committee on Biological Standardization 932, 55th report. Recommendations for the preparation, characterization and establishment of international and other biological reference preparations [revised 2004]. [accessed 22.08.11]. http://www.who.int/biologicals/expert_committee/TRS932CVR%2520with%2520full%2520Texts.pdf.
17. Hung I.F., To K.K., Lee C.K., Lin C.K., Chan J.F., Tse H., et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010, 51:274-279.
18. Veguilla V., Hancock K., Schiffer J., Gargiullo P., Lu X., Aranio D., et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011, 49(6):2210-2215.
19. WHO. WHO manual on animal influenza diagnosis and surveillance. [accessed 22.08.11]. http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf.
20. World Health Organisation. H1 IS World Health Organisation Expert Committee on Biological Standardization. Report of a WHO collaborative study to assess the suitability of a candidate International Standard for antibody to pandemic H1N1 influenza virus. WHO/BS/10 2137 2010.
21. World Health Organization. 2nd WHO consultation on global action plan for influenza vaccines. [accessed 22.08.11]. http://www.who.int/influenza_vaccines_plan/en/.
22. Wagner R, Göpferta C, Hammanna J, Neumanna B, Wood J, Newman R, et al. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine, submitted for publication.